Quantcast

Latest Protein-bound paclitaxel Stories

2014-05-20 08:34:22

AADi Initiates NIH Funded Clinical Trial for Patients with Bladder Cancer PACIFIC PALISADES, Calif., May 20, 2014 /PRNewswire/ -- AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches, today announced the inlicensing of ABI-009 from Celgene Corporation (NASDAQ:CELG). ABI-009 is the nanoparticle albumin-bound (nab®) version of the mTOR inhibitor sirolimus or rapamycin and leverages the same technology of the...

2014-04-04 12:27:03

SAN DIEGO, April 4, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq(TM) and Abraxane(®) (nab-paclitaxel) pharmacokinetics (PK) from animal studies. The PK data will be presented by Dr. Kouros Motamed, Vice President of Clinical Development & Nanomedicine on April 9 from 8:00 AM to...

2014-04-01 00:21:53

SAN DIEGO, March 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer. The registration trial referred to as TRIBECA(TM) (TRIal designed to evaluate BioEquivalence...

2014-03-26 08:29:22

Company Seeking Global Marketing Partners for its Proprietary Vitamin B-12 Drug Delivery Technology NEW YORK, March 26, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that it is leveraging its proprietary CobaCyte(TM) drug delivery platform technology to create new formulations of active pharmaceutical agents. Access recently submitted an additional patent application to protect improvements in the technology and...

2014-03-18 08:32:43

-- ABRAXANE plus gemcitabine approved by the TGA for the first-line treatment of metastatic pancreatic cancer MELBOURNE, Australia, March 18, 2014 /PRNewswire/ -- Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE(®) (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved...

2014-03-06 08:29:53

SAN DIEGO, March 6, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that it will present a comparison of the pharmacokinetic (PK) properties of Cynviloq and nab-paclitaxel (Abraxane(®)) at the 31(st )Annual Miami Breast Cancer Conference in Miami Beach, Florida. Highlights of the findings include new and historical data on PK bioequivalence of...

2014-02-11 08:32:10

SAN DIEGO, Feb. 11, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that it will present results of preclinical and Phase II clinical studies of Cynviloq(TM) in patients with metastatic pancreatic cancer at the Beaujon International Conference: Cutting Edge in Liver and Pancreatic Tumors in Paris, France on February 13, 2014. Highlights of the...

2014-02-10 16:26:58

SAN DIEGO, Feb. 10, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today the Company has obtained exclusive rights to Cynviloq(TM) (marketed as Genexol-PM(®) in South Korea and other countries) in Australia, Canada and Mexico from Samyang Biopharmaceuticals ("Samyang"), a South Korean corporation. Sorrento already has exclusive rights from Samyang for...

2014-01-17 20:21:56

MELBOURNE, Australia, Jan. 17, 2014 /PRNewswire/ -- -- Study shows ABRAXANE plus gemcitabine combination therapy further extends overall survival benefit -- First Phase III trial in metastatic pancreatic cancer to report three year survival rates[1] -- New standard of care for patients with metastatic pancreatic cancer A leading breast cancer drug, ABRAXANE(®)( )(nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for...

2013-10-17 16:30:52

NEJM today publishes findings of international trial resulting in recent FDA approval of Abraxane (nab-paclitaxel) for patients with advanced pancreatic cancer By all measures, the addition of nab-paclitaxel for the treatment of patients with advanced pancreatic cancer was superior to the survival for patients who received only gemcitabine, according to the results of a study led by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, published today by The New...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related